Asset Details
Do you wish to reserve the book?
Ursolic Acid and Solasodine as Potent Anti-Mycobacterial Agents for Combating IParatuberculosis/I: An Anti-Inflammatory and In Silico Analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ursolic Acid and Solasodine as Potent Anti-Mycobacterial Agents for Combating IParatuberculosis/I: An Anti-Inflammatory and In Silico Analysis
Do you wish to request the book?
Ursolic Acid and Solasodine as Potent Anti-Mycobacterial Agents for Combating IParatuberculosis/I: An Anti-Inflammatory and In Silico Analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ursolic Acid and Solasodine as Potent Anti-Mycobacterial Agents for Combating IParatuberculosis/I: An Anti-Inflammatory and In Silico Analysis
2022
Overview
Mycobacterium avium subspecies paratuberculosis (MAP) infection in domestic livestock causes persistent diarrhea, weight loss, and death and is also a potential cause of Crohn’s disease (CD) in humans; notably, treatments against MAP are insufficient, costly, and can cause adverse reactions. Hence, plant-derived bioactive constituents have been taken into consideration in this regard. Herein, we present the results of two bioactive constituents (Solasodine and Ursolic acid) that were evaluated for their safety and efficacy against MAP protein (Dephospho-Coenzyme A kinase (DPCK) by utilizing in vitro assays and different tools of in silico biology. The ADME/t-test, the drug-likeness property test, pharmacophore modelling, and PASS prediction have proven that both the constituents have better binding capacities than the available antibiotic drugs used to target protein inhibition pathways. Through our observations, it can be inferred that these two phytochemicals can be adequately used to treat paratuberculosis, thereby combating inflammatory bowel disorders (IBD) of an autoimmune nature.
Publisher
MDPI AG
